Cargando…
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19
The rapid spread of a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to an ongoing pandemic of coronavirus disease 2019 (COVID-19). Recently, angiotensin-converting enzyme 2 (ACE2) has been shown to be a functional receptor for SARS-CoV-2 to enter host targe...
Autores principales: | Kai, Hisashi, Kai, Mamiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184165/ https://www.ncbi.nlm.nih.gov/pubmed/32341442 http://dx.doi.org/10.1038/s41440-020-0455-8 |
Ejemplares similares
-
Angiotensin II, RAS Activation, and RAS Blockers in COVID-19: Unambiguous Evidence
por: Calò, Lorenzo A., et al.
Publicado: (2022) -
Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies
por: Kai, Hisashi, et al.
Publicado: (2021) -
Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients
por: Osman, Ikram Omar, et al.
Publicado: (2021) -
Recombinant human ACE2: acing out angiotensin II in ARDS therapy
por: Zhang, Haibo, et al.
Publicado: (2017) -
Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)